

Nasal Potential Difference in suspected CF patients with 5T polymorphism *

Comparison between patients from Israel and Netherlands

Published: 04-09-2013

Last updated: 26-04-2024

Clarify the effect of 5T polymorphism with or without another CF causing mutation on the other allele, on the CFTR function.

Ethical review	Not approved
Status	Will not start
Health condition type	Congenital reproductive tract and breast disorders
Study type	Observational invasive

Summary

ID

NL-OMON39838

Source

ToetsingOnline

Brief title

NPD in 5T patients

Condition

- Congenital reproductive tract and breast disorders
- Respiratory disorders NEC

Synonym

Cystic Fibrosis, Mucoviscidosis

Research involving

Human

Sponsors and support

Primary sponsor: Universitair Medisch Centrum Utrecht

Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: 5T polymorphism, CF, CFTR function, NPD

Outcome measures

Primary outcome

Potential differences in NPD measurement.

Secondary outcome

None.

Study description

Background summary

For different CFTR mutations it is known that they can cause CF. However for some mutations in the CFTR gene it is not certain if they cause CF or in combination with which mutations they might. 5T polymorphism is one of those mutations. Persons who are homozygous for this mutation, or persons who have this mutation on one allele and have no CF causing mutation on the other, have an increased chance of CBAVD (congenital bilateral absence of vas deferens). Heterozygosity for 5T polymorphism combined with a known CF-causing mutation is associated with CF with atypical presentation. In Ashkenazi Jews this mutation is present in 18% of CF patients with atypical presentation, in non-Ashkenazi Jews this is 10%. In CBAVD in Ashkenazi Jews, 32% of cases is due to 5T polymorphism and in non-Ashkenazim this is 36%. This mutation is also present in other ethnic groups. It is not known to what extent this mutation in itself or in combination with another mutation leads to a reduction in CFTR function, and to what extent this leads to health complaints. Through this study we want to clarify this. Possibly CFTR function is dependent on the mutation that is present on the other CFTR allele. Those mutations probably differ between the Dutch and Israeli population, which is why we want to compare Israeli patients (data already available) with Dutch patients.

Study objective

Clarify the effect of 5T polymorphism with or without another CF causing mutation on the other allele, on the CFTR function.

Study design

An NPD test is performed in about 30 persons with a 5T polymorphism. The average values of the test are calculated for the group of 5T homozygotes and for the group of persons with one 5T in combination with another CF causing mutation. These values are compared with the reference values for NPD. Through an ANOVA test the significance of the difference between the outcomes of the groups is assessed.

Additionally the 95% CI is calculated per group and overlap in the values is evaluated.

The same is done for the patients in Israel, and the Dutch patient groups will be compared to the Israeli patient groups.

Study burden and risks

The burden and risk of participation are minimal.

The patient needs to sit still throughout the measurement in a neutral position.

The salt solutions and subcutaneous needle used, are safe. Some irritation or bleeding of the nasal mucosa may occur.

Contacts

Public

Universitair Medisch Centrum Utrecht

Heidelberglaan 100
Utrecht 3584 CX
NL

Scientific

Universitair Medisch Centrum Utrecht

Heidelberglaan 100
Utrecht 3584 CX
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Elderly (65 years and older)

Inclusion criteria

presence of 5T polymorphism on one or both alleles

Exclusion criteria

chronic irritation of nasal epithelium

Study design

Design

Study type: Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Basic science

Recruitment

NL

Recruitment status: Will not start

Enrollment: 30

Type: Anticipated

Ethics review

Not approved
Date: 04-09-2013
Application type: First submission
Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
CCMO	NL42164.041.12